Transcultural Validation in French of the Systemic Lupus Activity Questionnaire (SLAQ) and the Lupus Quality Of Life (LupusQoL) Questionnaire (FRESH COLA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02857452|
Recruitment Status : Completed
First Posted : August 5, 2016
Last Update Posted : August 5, 2016
The evaluation of lupus patients must include several approaches, in particular disease activity and quality of life.
The Systemic Lupus Activity Questionnaire (SLAQ) is a validated self-questionnaire to evaluate disease activity. It has the advantage of being inexpensive, easy to use in large cohorts and has been used in several studies. It has never been validated in French. The Lupus Quality Of Life (LupusQoL) is a self-questionnaire to evaluate quality of life and is specific to systemic lupus erythematous; it was developed from interviews with patients.
This tool, validated in a British population, has never been validated in French.
|Condition or disease||Intervention/treatment|
|Lupus||Other: SLA Questionnaire Other: Lupus Qol Questionnaire|
|Study Type :||Observational|
|Actual Enrollment :||162 participants|
|Official Title:||Transcultural Validation in French of the Systemic Lupus Activity Questionnaire (SLAQ) and the Lupus Quality Of Life (LupusQoL) Questionnaire|
|Study Start Date :||January 2009|
|Actual Primary Completion Date :||February 2010|
Other: SLA Questionnaire
Other: Lupus Qol Questionnaire
- Answers in French to the au Systemic Lupus Activity Questionnaire (SLAQ) [ Time Frame: Evolution of answers between D0, D15, M3 and M6 ]
- Answers in French to the Lupus Quality of Life (Lupus QoL) questionnaire [ Time Frame: Evolution of answers between D0, D15, M3 and M6 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02857452
|CHU Dijon Bourgogne|
|Dijon, France, 21079|